Physician profile
Thomas T Tran
NPI 1104843705
$1,478.14
in general payments reported to CMS, 2019-2025
14 companies · $531 in 2025
The $531 reported for 2025 was more than what 75% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $257 · 2020: $160 · 2021: $87.71 · 2022: $94.10 · 2023: $71.81 · 2024: $276 · 2025: $531.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $879.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $878.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $260.62 | 2024-2025 | Entyvio |
| Abbvie INC. | $210.29 | 2019-2024 | |
| Boston Scientific Corporation | $204.13 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $145.34 | 2019-2024 | Trulance |
| Astrazeneca Pharmaceuticals LP | $135.77 | 2025 | Farxiga, Breztri |
| Alkermes, INC. | $125.00 | 2020 | |
| Janssen Biotech, INC. | $102.90 | 2025 | Simponi, Simponi Aria, Stelara |
| Evoke Pharma, INC. | $95.38 | 2023-2025 | Gimoti |
| Genentech USA, INC. | $78.62 | 2022 | |
| Novo Nordisk INC | $36.88 | 2023 | Ozempic, Rybelsus |
| Alnylam Pharmaceuticals INC. | $28.21 | 2025 | Givlaari |
| Ferring Pharmaceuticals INC. | $27.24 | 2025 | Rebyota |
| Lilly USA, LLC | $15.08 | 2023 | Jardiance, Emgality |
| Allergan, INC. | $12.68 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Tran listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.